Improving Provider and Patient Acceptance of Biosimilars in Treating Cancer

Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.

A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.

CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.

Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.